(Q44225494)

1 December 2017

title

Management of metastatic renal cell carcinoma in the era of targeted therapies (English)

1 reference

metastatic renal cell carcinoma

1 December 2017

1 reference

1 reference

1

1 reference

1 December 2017

A Cooper

2

1 reference

1 December 2017

H Kleiven

series ordinal

3

1 reference

1 December 2017

D Yip

series ordinal

4

1 reference

1 December 2017

D Goldstein

series ordinal

5

1 reference

1 December 2017

publication date

1 August 2011

1 reference

Internal Medicine Journal

1 December 2017

published in

1 reference

1 December 2017

volume

41

1 reference

1 December 2017

issue

8

1 reference

1 December 2017

page(s)

594-605

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

1 December 2017

1 reference

The genetic basis of cancer of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02540.X

10.1111/J.1445-5994.2011.02540.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference